Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex Straumann

Showing results (121-130 of 175) with videos related to

Pageof 18
Sort By:
United European Gastroenterology Journal|December 5, 2020
Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohortThomas Greuter, Frédéric Porchet, Manuel B Braga-Neto, et al.
Therapeutic Advances in Gastroenterology|March 1, 2018
Low serum zinc levels predict presence of depression symptoms, but not overall disease outcome, regardless of ATG16L1 genotype in Crohn's disease patientsThomas Greuter, Yannick Franc, Matthias Kaelin, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|September 19, 2025
Wide discrepancy between best practice recommendations and real-life management of suspected eosinophilic esophagitis-associated food bolus impactionYangzom Siegfried, Jagoda Pokryszka, Petr Hruz, et al.
Inflammatory Bowel Diseases|April 22, 2011
Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel diseaseStephan R Vavricka, Sabrina M Spigaglia, Gerhard Rogler, et al.
Gastrointestinal Endoscopy|May 18, 2021
Technical feasibility, clinical effectiveness, and safety of esophageal stricture dilation using a novel endoscopic attachment cap in adults with eosinophilic esophagitisAlain M Schoepfer, Sarah Henchoz, Luc Biedermann, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 25, 2020
Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic EsophagitisEvan S Dellon, Margaret H Collins, Marc E Rothenberg, et al.
Inflammatory Bowel Diseases|June 16, 2011
Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II surveyStephan R Vavricka, Alain M Schoepfer, Georg Bansky, et al.
Digestive Diseases (Basel, Switzerland)|June 9, 2017
Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III SurveyStephan R Vavricka, Milos Spasojevic, Gerhard Rogler, et al.
European Journal of Gastroenterology & Hepatology|February 1, 2018
Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease CohortSébastien Godat, Nicolas Fournier, Ekaterina Safroneeva, et al.
International Archives of Allergy and Immunology|October 22, 2023
Histological Phenotyping in Eosinophilic Esophagitis: Localized Proximal Disease Is Infrequent but Associated with Less Severe Disease and Better Disease OutcomeAlexis Heil, Tobias Kuehlewindt, Anne Godat, et al.
Pageof 18

Showing results (121-130 of 175) with videos related to

Sort By:
Pageof 18
United European Gastroenterology Journal|December 5, 2020
Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohortThomas Greuter, Frédéric Porchet, Manuel B Braga-Neto, et al.
Therapeutic Advances in Gastroenterology|March 1, 2018
Low serum zinc levels predict presence of depression symptoms, but not overall disease outcome, regardless of ATG16L1 genotype in Crohn's disease patientsThomas Greuter, Yannick Franc, Matthias Kaelin, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|September 19, 2025
Wide discrepancy between best practice recommendations and real-life management of suspected eosinophilic esophagitis-associated food bolus impactionYangzom Siegfried, Jagoda Pokryszka, Petr Hruz, et al.
Inflammatory Bowel Diseases|April 22, 2011
Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel diseaseStephan R Vavricka, Sabrina M Spigaglia, Gerhard Rogler, et al.
Gastrointestinal Endoscopy|May 18, 2021
Technical feasibility, clinical effectiveness, and safety of esophageal stricture dilation using a novel endoscopic attachment cap in adults with eosinophilic esophagitisAlain M Schoepfer, Sarah Henchoz, Luc Biedermann, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 25, 2020
Long-term Efficacy and Tolerability of RPC4046 in an Open-Label Extension Trial of Patients With Eosinophilic EsophagitisEvan S Dellon, Margaret H Collins, Marc E Rothenberg, et al.
Inflammatory Bowel Diseases|June 16, 2011
Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II surveyStephan R Vavricka, Alain M Schoepfer, Georg Bansky, et al.
Digestive Diseases (Basel, Switzerland)|June 9, 2017
Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III SurveyStephan R Vavricka, Milos Spasojevic, Gerhard Rogler, et al.
European Journal of Gastroenterology & Hepatology|February 1, 2018
Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease CohortSébastien Godat, Nicolas Fournier, Ekaterina Safroneeva, et al.
International Archives of Allergy and Immunology|October 22, 2023
Histological Phenotyping in Eosinophilic Esophagitis: Localized Proximal Disease Is Infrequent but Associated with Less Severe Disease and Better Disease OutcomeAlexis Heil, Tobias Kuehlewindt, Anne Godat, et al.
Pageof 18